Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Top Indices
DJI
Nasdaq Composite
SPX
My Portfolio
Articles published by Regeneron Pharmaceuticals, Inc.
< Previous
1
2
3
Next >
Regeneron to Showcase Progress from Innovative Oncology Portfolio in Several Difficult-to-Treat Cancers at ESMO
October 15, 2023
From
Regeneron Pharmaceuticals, Inc.
Via
GlobeNewswire
Tickers
REGN
EYLEA® HD (aflibercept) Injection 8 mg Two-year Results from Pivotal PULSAR Trial in Wet Age-related Macular Degeneration Presented at EURETINA
October 05, 2023
From
Regeneron Pharmaceuticals, Inc.
Via
GlobeNewswire
Tickers
REGN
Regeneron and Intellia Announce Expanded Research Collaboration to Develop CRISPR-Based Therapies for the Treatment of Neurological and Muscular Diseases
October 03, 2023
From
Regeneron Pharmaceuticals, Inc.
Via
GlobeNewswire
Tickers
NTLA
REGN
Odronextamab BLA for Treatment of Relapsed/Refractory Follicular Lymphoma (FL) and Diffuse Large B-cell Lymphoma (DLBCL) Accepted for FDA Priority Review
September 29, 2023
From
Regeneron Pharmaceuticals, Inc.
Via
GlobeNewswire
Tickers
REGN
Regeneron to Report Third Quarter 2023 Financial and Operating Results and Host Conference Call and Webcast on November 2, 2023
September 28, 2023
From
Regeneron Pharmaceuticals, Inc.
Via
GlobeNewswire
Tickers
REGN
Dupixent® (dupilumab) sBLA for Treatment of Eosinophilic Esophagitis (EoE) in Children Aged 1 to 11 Accepted for FDA Priority Review
September 26, 2023
From
Regeneron Pharmaceuticals, Inc.
Via
GlobeNewswire
Tickers
REGN
SNY
Regeneron Completes Acquisition of Decibel Therapeutics, Adding Promising Gene Therapy Programs for Hearing Loss
September 25, 2023
From
Regeneron Pharmaceuticals, Inc.
Via
GlobeNewswire
Tickers
REGN
Regeneron Provides Update on Planned Chief Financial Officer Transition
September 08, 2023
From
Regeneron Pharmaceuticals, Inc.
Via
GlobeNewswire
Tickers
REGN
Regeneron Announces Updates to Board of Directors
September 08, 2023
From
Regeneron Pharmaceuticals, Inc.
Via
GlobeNewswire
Tickers
REGN
Regeneron Announces Investor Conference Presentations
August 23, 2023
From
Regeneron Pharmaceuticals, Inc.
Via
GlobeNewswire
Tickers
REGN
Regeneron Announces Agreement with BARDA Supporting Development of Next-Generation Antibody Therapy for COVID-19 Prevention
August 22, 2023
From
Regeneron Pharmaceuticals, Inc.
Via
GlobeNewswire
Tickers
REGN
EYLEA HD (aflibercept) Injection 8 mg Approved by FDA for Treatment of Wet Age-related Macular Degeneration (wAMD), Diabetic Macular Edema (DME) and Diabetic Retinopathy (DR)
August 18, 2023
From
Regeneron Pharmaceuticals, Inc.
Via
GlobeNewswire
Tickers
REGN
Veopoz™ (pozelimab-bbfg) Receives FDA Approval as the First Treatment for Children and Adults with CHAPLE Disease
August 18, 2023
From
Regeneron Pharmaceuticals, Inc.
Via
GlobeNewswire
Tickers
REGN
Odronextamab Receives EMA Filing Acceptance for Treatment of Relapsed/Refractory Follicular Lymphoma and Diffuse Large B-cell Lymphoma
August 17, 2023
From
Regeneron Pharmaceuticals, Inc.
Via
GlobeNewswire
Tickers
REGN
Two-year PULSAR Trial Results for Aflibercept 8 mg Demonstrate Durable Vision Gains at Extended Dosing Intervals in Wet Age-related Macular Degeneration
August 10, 2023
From
Regeneron Pharmaceuticals, Inc.
Via
GlobeNewswire
Tickers
REGN
Regeneron Reports Second Quarter 2023 Financial and Operating Results
August 03, 2023
From
Regeneron Pharmaceuticals, Inc.
Via
GlobeNewswire
Tickers
REGN
Regeneron Announces the 2023 Winners of The Regeneron Prize for Creative Innovation
August 01, 2023
From
Regeneron Pharmaceuticals, Inc.
Via
GlobeNewswire
Tickers
REGN
Aflibercept 8 mg Two-Year Results from Pivotal PHOTON Trial in Diabetic Macular Edema Presented at ASRS
July 29, 2023
From
Regeneron Pharmaceuticals, Inc.
Via
GlobeNewswire
Tickers
REGN
Regeneron to Report Second Quarter 2023 Financial and Operating Results and Host Conference Call and Webcast on August 3, 2023
June 29, 2023
From
Regeneron Pharmaceuticals, Inc.
Via
GlobeNewswire
Tickers
REGN
Two-year Results for Aflibercept 8 mg from Pivotal PHOTON Trial Demonstrate Durable Vision Gains at Extended Dosing Intervals in Diabetic Macular Edema
June 27, 2023
From
Regeneron Pharmaceuticals, Inc.
Via
GlobeNewswire
Tickers
REGN
FDA Issues Complete Response Letter (CRL) for Aflibercept 8 mg Biologics License Application Solely Due to an Ongoing Review of Inspection Findings at a Third-party Filler
June 27, 2023
From
Regeneron Pharmaceuticals, Inc.
Via
GlobeNewswire
Tickers
REGN
Updated Linvoseltamab (BCMAxCD3) Data from Pivotal Trial Demonstrates Early, Deep and Durable Responses in Patients with Heavily Pre-treated Multiple Myeloma
May 25, 2023
From
Regeneron Pharmaceuticals, Inc.
Via
GlobeNewswire
Tickers
REGN
Fianlimab (LAG-3 inhibitor) Combined with Libtayo® (cemiplimab) Shows Clinically Meaningful and Durable Tumor Responses Across Key Advanced Melanoma Patient Populations
May 25, 2023
From
Regeneron Pharmaceuticals, Inc.
Via
GlobeNewswire
Tickers
REGN
Dupixent® (dupilumab) Late-breaking Phase 3 COPD Results Presented at ATS and Simultaneously Published in the New England Journal of Medicine
May 21, 2023
From
Regeneron Pharmaceuticals, Inc.
Via
GlobeNewswire
Tickers
REGN
High School Scientists and Engineers Win Nearly $9 Million at the Regeneron International Science and Engineering Fair 2023
May 19, 2023
From
Regeneron Pharmaceuticals, Inc.
Via
GlobeNewswire
Tickers
REGN
Regeneron Announces Investor Conference Presentations
May 18, 2023
From
Regeneron Pharmaceuticals, Inc.
Via
GlobeNewswire
Tickers
REGN
Regeneron Applauds Supreme Court’s Unanimous Opinion Striking Down Amgen’s PCSK9 Patent Claims and Supporting Scientific Innovation
May 18, 2023
From
Regeneron Pharmaceuticals, Inc.
Via
GlobeNewswire
Tickers
REGN
Regeneron Reports First Quarter 2023 Financial and Operating Results
May 04, 2023
From
Regeneron Pharmaceuticals, Inc.
Via
GlobeNewswire
Tickers
REGN
Regeneron to Highlight New and Updated Clinical Data at ASCO Showcasing Breadth of Cancer Research
May 02, 2023
From
Regeneron Pharmaceuticals, Inc.
Via
GlobeNewswire
Tickers
REGN
Regeneron and Alnylam Report Positive Interim Phase 1 Clinical Data on ALN-APP, an Investigational RNAi Therapeutic for Alzheimer’s Disease and Cerebral Amyloid Angiopathy
April 26, 2023
From
Regeneron Pharmaceuticals, Inc.
Via
GlobeNewswire
Tickers
ALNY
REGN
< Previous
1
2
3
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.